Pluri Inc.PLUR
Price (close)
$1.05
Market cap
$11.4M
P/E
—
Revenue (TTM)
$1.0M
Net income
-$23.8M
Dividend yield
—
1-year total return
-76.9%
Net margin
-2344.6%
Revenue growth
-24.0%
Debt / equity
—
What Pluri Inc. does.
leveraging our proprietary 3D cell expansion platform, which is supported by an in-house, industrial-scale cell manufacturing facility
and operates in accordance with Good Manufacturing Practice (“GMP”) standards on a self-declared basis. Our platform is designed
to enable scalable, cost-efficient and reproducible expansion of human, plant and animal cells and supports cell-based products, services,
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue | — | $234,000 | $287,000 | $326,000 | $1.3M | $1.0M |
| Net income | -$49.9M | -$41.2M | -$28.3M | -$20.9M | -$22.6M | -$23.8M |
| Free cash flow | -$31.3M | -$36.8M | -$23.1M | -$18.3M | -$19.8M | -$20.2M |
More on PLUR.
- Pluri Inc. summary
- Pluri Inc. financial statements
- Pluri Inc. key metrics
- Pluri Inc. health scores and style box
- Pluri Inc. earnings
- Pluri Inc. dividends
- Pluri Inc. valuation
- Pluri Inc. ownership and insiders
- Pluri Inc. peers
Figures from Pluri Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.